RGEN - レプリジェン (Repligen Corporation) レプリジェン

 RGENのチャート


 RGENの企業情報

symbol RGEN
会社名 Repligen Corp. (レプリジェン)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 医薬品   医療関連(Health Care)
概要 事業概要 レプリゲン(Repligen Corporation)はバイオプロセス会社である。同社は生物医薬品製造プロセスの相互接続段階を改善するために使用される製品の開発、製造、および商品化に注力する。同社のポートフォリオには、タンパク質製品、クロマトグラフィー製品、ろ過製品が含まれる。同社は市場または開発中のモノクローナル抗体(mAb)ベースの薬物の精製に使用されるプロテインAクロマトグラフィー樹脂の成分であるプロテインAリガンドを提供する。クロマトグラフィーのポートフォリオには生物学的薬剤の下流精製および品質管理に使用される製品が含まれる。OPUSプレパッククロマトグラフィーカラム(PPC)は臨床段階の生物製剤の精製に使用される。ろ過製品には、XCell交互タンジェンシャル・フロー(ATF)システムおよびSiusタンジェンシャル・フロー・フィルトレーション(TFF)カセットが含まれる。Sius TFFカセットは臨床および商業段階の生物製剤を濃縮するために使用される。   レプリジェンは米国のバイオテクノロジ―企業。世界の生命科学企業やバイオ医薬品メ―カ―向けに、生物学的処理に使用される製品の開発、製造、販売を行う。中央神経系疾患の治療薬開発を中心に事業を展開する。また、モノクロ―ナル抗体治療薬の分離と精製に用いられる、親和性リガンド「プロテインA」の製造に従事。本社はマサチュ―セッツ州。   Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.
本社所在地 41 Seyon Street Bldg. 1 Suite 100 Waltham MA 02453 USA
代表者氏名 Karen A. Dawes カレンA.ダウズ
代表者役職名 Independent Chairperson of the Board
電話番号 +1 781-449-9560
設立年月日 29707
市場名 NASDAQ National Market System
ipoyear 1986年
従業員数 476人
url www.repligen.com
nasdaq_url https://www.nasdaq.com/symbol/rgen
adr_tso
EBITDA EBITDA(百万ドル) 28.26800
終値(lastsale) 54.7
時価総額(marketcap) 2396177369.4
時価総額 時価総額(百万ドル) 2415.89
売上高 売上高(百万ドル) 170.75300
企業価値(EV) 企業価値(EV)(百万ドル) 2341.608
当期純利益 当期純利益(百万ドル) 13.44700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Repligen Corporation revenues increased 47% to $92.6M. Net income decreased 46% to $6.2M. Revenues reflect North America segment increase from $11.6M to $42.7M. Net income was offset by Other selling increase of 30% to $23.2M (expense) Research and development - Balancing val increase from $3.4M to $8.7M (expense).

 RGENのテクニカル分析


 RGENのニュース

   Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for  2020/04/29 16:33:59 Zacks Investment Research
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update  2020/04/28 11:36:28 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) AstraZeneca plc (NYSE: AZN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioSig Technologies Inc (NASDAQ: BSGM ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Cytosorbents Corp (NASDAQ: CTSO ) DexCom, Inc. (NASDAQ: DXCM ) Erytech Pharma SA (NASDAQ: ERYP ) Exelixis, Inc. (NASDAQ: EXEL ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) I-Mab ADR (NASDAQ: IMAB ) Imara Inc (NASDAQ: IMRA ) Incyte Corporation (NASDAQ: INCY ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Keros Therapeutics Inc (NASDAQ: KROS ) Masimo Corporation (NASDAQ: MASI ) Novo Nordisk A/S (NYSE: NVO ) OraSure Technologies, Inc. (NASDAQ: OSUR ) Quidel Corporation (NASDAQ: QDEL ) REDHILL BIOPHAR/S ADR (NASDAQ: RDHL ) Repligen Corporation (NASDAQ: RGEN ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Translate Bio Inc (NASDAQ: TBIO ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) Vaxart Inc (NASDAQ: VXRT ) Vermillion, Inc. (NASDAQ: VRML ) West Pharmaceutical Services Inc. (NYSE: WST ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) Zynex Inc. (NASDAQ: ZYXI ) None of the Nasdaq- or NYSE-listed biotech/medical device/diagnostics company hit 52-week lows Monday.
   Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?  2020/03/21 15:30:56 Zacks Investment Research
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Repligen (RGEN) Stock Down Despite Q4 Earnings & Sales Beat  2020/02/21 09:32:00 Zacks Investment Research
Repligen's (RGEN) beats on both earnings and revenues in Q4. However, stock declines.
   The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study  2020/02/20 12:06:25 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Arcus Biosciences Inc (NYSE: RCUS ) Ascendis Pharma A/S (NASDAQ: ASND ) AVITA MED LTD/S ADR (NASDAQ: RCEL )(reacted to its half-yearly results) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) ChemoCentryx Inc (NASDAQ: CCXI ) Cue Biopharma Inc (NASDAQ: CUE )(said its therapeutic Immuno-STAT platform will be featured in a Merck & Co., Inc.'s (NYSE: MRK ) presentation at the Antigen Specific Immune Tolerance Drug Development Summit) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB )(reacted to its quarterly and full-year results) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Insulet Corporation (NASDAQ: PODD ) Intuitive Surgical, Inc.
   Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?  2020/03/21 15:30:56 Zacks Investment Research
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Repligen (RGEN) Stock Down Despite Q4 Earnings & Sales Beat  2020/02/21 09:32:00 Zacks Investment Research
Repligen's (RGEN) beats on both earnings and revenues in Q4. However, stock declines.
   The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study  2020/02/20 12:06:25 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Arcus Biosciences Inc (NYSE: RCUS ) Ascendis Pharma A/S (NASDAQ: ASND ) AVITA MED LTD/S ADR (NASDAQ: RCEL )(reacted to its half-yearly results) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) ChemoCentryx Inc (NASDAQ: CCXI ) Cue Biopharma Inc (NASDAQ: CUE )(said its therapeutic Immuno-STAT platform will be featured in a Merck & Co., Inc.'s (NYSE: MRK ) presentation at the Antigen Specific Immune Tolerance Drug Development Summit) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB )(reacted to its quarterly and full-year results) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Insulet Corporation (NASDAQ: PODD ) Intuitive Surgical, Inc.
   Repligen (RGEN) is an Incredible Growth Stock: 3 Reasons Why  2020/02/19 17:45:06 Zacks Investment Research
Repligen (RGEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
   Earnings Preview: Repligen (RGEN) Q4 Earnings Expected to Decline  2020/02/13 17:31:18 Zacks Investment Research
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?  2020/03/21 15:30:56 Zacks Investment Research
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Repligen (RGEN) Stock Down Despite Q4 Earnings & Sales Beat  2020/02/21 09:32:00 Zacks Investment Research
Repligen's (RGEN) beats on both earnings and revenues in Q4. However, stock declines.
   The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study  2020/02/20 12:06:25 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Arcus Biosciences Inc (NYSE: RCUS ) Ascendis Pharma A/S (NASDAQ: ASND ) AVITA MED LTD/S ADR (NASDAQ: RCEL )(reacted to its half-yearly results) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) ChemoCentryx Inc (NASDAQ: CCXI ) Cue Biopharma Inc (NASDAQ: CUE )(said its therapeutic Immuno-STAT platform will be featured in a Merck & Co., Inc.'s (NYSE: MRK ) presentation at the Antigen Specific Immune Tolerance Drug Development Summit) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB )(reacted to its quarterly and full-year results) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Insulet Corporation (NASDAQ: PODD ) Intuitive Surgical, Inc.
   Repligen (RGEN) is an Incredible Growth Stock: 3 Reasons Why  2020/02/19 17:45:06 Zacks Investment Research
Repligen (RGEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
   Earnings Preview: Repligen (RGEN) Q4 Earnings Expected to Decline  2020/02/13 17:31:18 Zacks Investment Research
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

 関連キーワード  (医薬品 米国株 レプリジェン RGEN Repligen Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)